Hormonal
SGLT2 inhibitors (empagliflozin) and GLP-1 receptor agonists (liraglutide) significantly reduce cardiovascular mortality and major adverse cardiovascular events (MACE) in high-risk type 2 diabetes patients, unlike earlier glucose-lowering agents which showed neutral or negative effects.
If you have type 2 diabetes and established heart disease, ask your doctor about empagliflozin or liraglutide. These drugs have proven to reduce the risk of heart attack, stroke, and heart failure hospitalization, and even death from cardiovascular causes, beyond just lowering blood sugar. This is particularly relevant if you have kidney issues or heart failure.
the EMPA-REG Outcome trial and the LEADER trial have shown superiority of the SGLT2-I empagliflozin and the GLP-1RA liraglutide, respectively, on the 3-point MACE outcome (cardiovascular death, non-fatal myocardial infarction or stroke) and cardiovascular, as well as all-cause mortality.
Why this rating
Based on large, placebo-controlled cardiovascular outcome trials (CVOTs) like EMPA-REG and LEADER.
Source
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
Angelo Avogaro et al. · Cardiovascular Diabetology · 2016
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →